Peptides binding to prostate-specific antigen enhance its antiangiogenic activity

Prostate

Volumn 72, Issue 14, 2012, Pages 1588-1594

  Mattsson, Johanna M ^a   Närvänen, Ale ^b   Stenman, Ulf Håkan ^a   Koistinen, Hannu ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

endothelial cells; kallikrein related peptidase; prostate cancer; tube formation

Indexed keywords

MATRIGEL; PROSTATE SPECIFIC ANTIGEN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN BINDING; UMBILICAL VEIN ENDOTHELIAL CELL;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES, CYCLIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STATISTICS, NONPARAMETRIC;

EID: 84865513594     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22512     Document Type: Article

References (38)

1. Coombs GS, Bergstrom RC, Pellequer JL, Baker SI, Navre M, Smith MM, Tainer JA, Madison EL, Corey DR,. Substrate specificity of prostate-specific antigen (PSA). Chem Biol 1998; 5: 475-488. (Pubitemid 28436726)
2. Mattsson JM, Valmu L, Laakkonen P, Stenman UH, Koistinen H,. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid. Prostate 2008; 68: 945-954. (Pubitemid 351794159)
3. Lilja H, Oldbring J, Rannevik G, Laurell CB,. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987; 80: 281-285.
4. Robert M, Gibbs BF, Jacobson E, Gagnon C,. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry 1997; 36: 3811-3819. (Pubitemid 27154701)
5. Stenman UH, Leinonen J, Zhang WM, Finne P,. Prostate-specific antigen. Semin Cancer Biol 1999; 9: 83-93. (Pubitemid 29265524)
6. Stege R, Grande M, Carlstrom K, Tribukait B, Pousette A,. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 2000; 6: 160-165. (Pubitemid 30064989)
7. Papadopoulos I, Sivridis E, Giatromanolaki A, Koukourakis MI,. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin Cancer Res 2001; 7: 1533-1538. (Pubitemid 32708616)
8. Ben Jemaa A, Bouraoui Y, Sallami S, Banasr A, Ben Rais N, Ouertani L, Nouira Y, Horchani A, Oueslati R,. Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies. J Exp Clin Cancer Res 2010; 29: 171.
9. Fortier AH, Nelson BJ, Grella DK, Holaday JW,. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999; 91: 1635-1640. (Pubitemid 29479930)
10. Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, Holland-Linn J, Vu H, Plum SM, Nelson BJ,. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 2003; 56: 212-219. (Pubitemid 36918172)
11. Mattsson JM, Laakkonen P, Stenman UH, Koistinen H,. Antiangiogenic properties of prostate-specific antigen (PSA). Scand J Clin Lab Invest 2009; 69: 447-451.
12. Lawrence MG, Lai J, Clements JA,. Kallikreins on steroids: Structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 2010; 31: 407-446.
13. Wu P, Leinonen J, Koivunen E, Lankinen H, Stenman UH,. Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur J Biochem 2000; 267: 6212-6220.
14. Pakkala M, Jylhäsalmi A, Wu P, Leinonen J, Stenman UH, Santa H, Vepsaläinen J, Peräkylä M, Närvänen A,. Conformational and biochemical analysis of the cyclic peptides which modulate serine protease activity. J Pept Sci 2004; 10: 439-447. (Pubitemid 39089269)
15. Wu P, Zhu L, Stenman UH, Leinonen J,. Immunopeptidometric assay for enzymatically active prostate-specific antigen. Clin Chem 2004; 50: 125-129. (Pubitemid 38125708)
16. Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH,. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995; 41: 1567-1573.
17. Denmeade SR, Lou W, Lovgren J, Malm J, Lilja H, Isaacs JT,. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997; 57: 4924-4930. (Pubitemid 27469004)
18. Kubota Y, Kleinman HK, Martin GR, Lawley TJ,. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 1988; 107: 1589-1598.
19. Lawley TJ, Kubota Y,. Induction of morphologic differentiation of endothelial cells in culture. J Invest Dermatol 1989; 93 (2 Suppl): 59S-61S.
20. Stenman UH, Paus E, Allard WJ, Andersson I, Andres C, Barnett TR, Becker C, Belenky A, Bellanger L, Pellegrino CM, Bormer OP, Davis G, Dowell B, Grauer LS, Jette DC, Karlsson B, Kreutz FT, van der Kwast TM, Lauren L, Leinimaa M, Leinonen J, Lilja H, Linton HJ, Nap M, Nilsson O, Ng PC, Nustad K, Peter A, Pettersson K, Piironen T, Rapp J, Rittenhouse HG, Rye PD, Seguin P, Slota J, Sokoloff RL, Suresh MR, Very DL, Wang TJ, Wigheden I, Wolfert RL, Yeung KK, Zhang W-M, Zhou Z, Hilgers J,. Summary report of the TD-3 workshop: Characterization of 83 antibodies against prostate-specific antigen. Tumour Biol 1999; 20 (Suppl 1): 1-12.
21. Nilsson O, Andersson I, Peter A, Karlsson B,. Characterization of antibodies to prostate-specific antigen. Tumour Biol 1999; 20 (Suppl 1): 43-51.
22. Folkman J,. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
23. Koistinen H, Närvänen A, Pakkala M, Hekim C, Mattsson JM, Zhu L, Laakkonen P, Stenman UH,. Development of peptides specifically modulating the activity of KLK2 and KLK3. Biol Chem 2008; 389: 633-642. (Pubitemid 352009409)
24. Vailhe B, Vittet D, Feige JJ,. In vitro models of vasculogenesis and angiogenesis. Lab Invest 2001; 81: 439-452. (Pubitemid 32298789)
25. Staton CA, Reed MW, Brown NJ,. A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol 2009; 90: 195-221.
26. Koistinen H, Wohlfahrt G, Mattsson JM, Wu P, Lahdenperä J, Stenman UH,. Novel small molecule inhibitors for prostate-specific antigen. Prostate 2008; 68: 1143-1151.
27. Chadha KC, Nair BB, Chakravarthi S, Zhou R, Godoy A, Mohler JL, Aalinkeel R, Schwartz SA, Smith GJ,. Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities. Prostate 2011; 71: 1680-1690.
28. Malm J, Hellman J, Hogg P, Lilja H,. Enzymatic action of prostate-specific antigen (PSA or hK3): Substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate 2000; 45: 132-139.
29. Pakkala M, Weisell J, Hekim C, Vepsäläinen J, Wallen EA, Stenman UH, Koistinen H, Närvänen A,. Mimetics of the disulfide bridge between the N- and C-terminal cysteines of the KLK3-stimulating peptide B-2. Amino Acids 2010; 39: 233-242.
30. Christensson A, Laurell CB, Lilja H,. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: 755-763.
31. Borgono CA, Diamandis EP,. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4: 876-890. (Pubitemid 39472954)
32. Webber MM, Waghray A, Bello D,. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995; 1: 1089-1094.
33. 2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett 2004; 207: 79-87. (Pubitemid 38429889)
34. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG,. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75: 1046-1053.
35. Williams SA, Jelinek CA, Litvinov I, Cotter RJ, Isaacs JT, Denmeade SR,. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate 2011; 71: 1595-1607.
36. Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J, Han R, Ma T, Kuo HC, Chang C,. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res 2008; 68: 7110-7119.
37. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J,. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 344: 1594-1598. (Pubitemid 24365358)
38. Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, Bjartell AS, Scardino PT, Ulmert D, Vickers AJ,. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011; 117: 1210-1219.